You just read:

Optimer Announces that the U.S. Food and Drug Administration's Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)

News provided by

Optimer Pharmaceuticals, Inc.

Apr 05, 2011, 04:48 ET